Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Antineoplastic Agents

All Drugs and Chemicals

Patritumab deruxtecan

Antineoplastic Agents, Immunological

5.6 mg/kg patritumab deruxtecan every 3 weeks

Day 1, day 3, day 6, day 11 and day 26 of first course

89Zr-Patritumab deruxtecan

Joop de Langen, MD

Marianne Mahn, MSc

Activity of patritumab deruxtecan (U3-1402; HER3-DXd) has been shown in a phase I/II study in patients with HER3 expressing breast cancer as well as in a phase I study in patients with EGFR TKI refractory EGFR mutation positive NSCLC with a preliminary ORR of 25%. HER3 expression can be seen in multiple tumor types and is therefore an attractive target for antibody drug conjugate (ADC) treatment. However, intra- and intertumor heterogeneity of HER3 expression might be substantial, as is seen for HER2, and might contribute to treatment failure or heterogeneous responses. In addition, HER3 expression is dynamic and has been shown to change over time.

In order to identify patients that may benefit most from treatment with patritumab deruxtecan, better knowledge of the in vivo behaviour of the drug is warranted. One way to visualize this behaviour is positron emission tomography (PET) imaging with radiolabelled antibodies (immune-PET). 89Zr-Patritumab deruxtecan PET/CT can assess HER3 expression non-invasively at a whole body level, including sites that may be difficult to biopsy. It also visualizes and quantifies biodistribution of patritumab deruxtecan, thereby obtaining valuable information for safety and toxicity analyses.

Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT

Identification of the optimal non-radiolabeled patritumab deruxtecan dose to be co-injected with 89Zr-Patritumab deruxtecan to allow optimal 89Zr-Patritumab deruxtecan PET imaging.

Quantify tumor 89Zr-Patritumab deruxtecan uptake (visually and quantitatively, expressed as SUV).

Daiichi Sankyo

The Netherlands Cancer Institute

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT	NCT06222489	Non-Small Cell ... Advanced Non-Sm... EGFR Gene Mutat...	89Zr-Patritumab...	18 Years -	The Netherlands Cancer Institute
Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT	NCT06222489	Non-Small Cell ... Advanced Non-Sm... EGFR Gene Mutat...	89Zr-Patritumab...	18 Years -	The Netherlands Cancer Institute

Spots Global Cancer Trial Database for at least one line of systemic treatment